Monensin Solution (1,000X)

Pricing & Availability
Regulatory Status
RUO
Ave. Rating
Submit a Review
Product Citations
publications
Cat # Size Price Save
420701 1 mL ¥10,500
Description

Monensin is a protein transport inhibitor commonly used to enhance intracellular cytokine staining signals by blocking transport processes during cell activation. Especially useful for the intracellular staining of cytokines, monensin leads to the accumulation of most cytokines at the Golgi Complex/Endoplasmic Reticulum (see Jung, et al., 1993). Optimal conditions for use are cell type and time-dependent. Typically, protein transport inhibitors are included during in vitro cell activation cultures for 4-24 hours prior to harvest (see references below for additional information). Monensin Solution is supplied as a 1,000X solution, which should be diluted to 1X in cell culture medium.

Product Details
Technical data sheet

Product Details

Formulation
Monensin Solution is supplied as a 1000X working solution in 70% Ethanol. Dilute to 1X in cell culture medium.
Concentration
2.0 mM
Storage & Handling
Store the solution between 2°C and 8°C. Monensin is known to be toxic; avoid direct body contact. Ethanol is flammable; keep away from sources of fire.
Application

ICFC - Quality tested

Recommended Usage

Dilute the 1000X solution to 1X in the tissue culture medium. It is recommended that cells are cultured with monensin for ≤ 24 hours, as this can become toxic for cell viability.

Application References

(PubMed link indicates BioLegend citation)
  1. Smeltz RB. 2007. J. Immunol. 178:4786.
  2. Fuse S, et al. 2007. J. Immunol. 178:5227.
  3. Durkin ET,et al. 2008. Blood 10:1182.PubMed
  4. Durkin ET, et al. 2008. Blood 112:5245. PubMed
  5. Liu XS, et al. 2009. J. Immunol. 183:51. PubMed
  6. Mattarollo SR, et al. 2010. J. Immunol. 184:1242. PubMed
  7. Yang M, et al. 2010. J. Immuonl. 184:3321. PubMed
  8. Mattarollo SR, et al. 2010. J. Immunol. 184:5663. PubMed
  9. Wood MW, et al. 2011. Infect Immun. 79:708. PubMed
  10. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  11. Fiorenza S, et al. 2012. J. Immunol. 189:5622. PubMed
  12. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  13. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  14. Bunse CE, et al. 2013. PLoS One. 8:77925. PubMed
Product Citations
  1. Li D, et al. 2013. Clin Immunol. 149:411. PubMed
  2. Mattarollo S, et al. 2010. J Immunol. 184:1242. PubMed
  3. Qian Y, et al. 2021. Cell Reports. 36(8):109602. PubMed
  4. Andrew Mansour, Laurentiu Pop, Ellen Vitetta 2016. PLoS One. 11:e0167618. PubMed
  5. Asgari E, et al. 2013. Blood. 122:3473. PubMed
  6. Munk R, et al. 2011. PLoS One. 6:e18553. PubMed
  7. Pan YG, et al. 2022. Methods Mol Biol. 2574:31. PubMed
  8. Aguilar-Pineda JA, et al. 2021. iScience. 24:102993. PubMed
  9. Bailey S, et al. 2017. Nat Commun.. 10.1038/s41467-017-01867-9. PubMed
  10. Durkin E, et al. 2008. Blood. 112:5245. PubMed
  11. Yang M, et al. 2010. J Immunol. 184:3321. PubMed
  12. Tian M, et al. 2022. J Clin Invest. 132:. PubMed
  13. Kimura I, et al. 2022. Cell Rep. 38:110218. PubMed
  14. Gao F, et al. 2021. Front Cell Infect Microbiol. 10:593805. PubMed
  15. Izumi K, et al. 2021. Immunohorizons. 5:687. PubMed
  16. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
  17. Martens A, et al. 2020. Nat Immunol. 21:381. PubMed
  18. Theeb W, et al. 2017. Infect Immun . 10.1128/IAI.00475-16. PubMed
  19. Al-Attar A, et al. 2016. Data Brief. 8: 536-44. PubMed
  20. Joosten S, et al. 2016. PLoS Pathog. 12: 1005687. PubMed
  21. Fiorenza S, et al. 2012. J Immunol. 189:5622. PubMed
  22. Rana A, et al. 2020. Front Immunol. 11:536. PubMed
  23. Datta A, et al. 2022. J Fungi (Basel). 8:. PubMed
  24. Douthwaite J, et al. 2017. J Immunol. 198(1):528-537. PubMed
  25. Meyer C, Key P 2017. Imm Inflam Dis. 10.1002/iid3.156. PubMed
  26. Montes de Oca M, et al. 2020. PLoS Pathog. 16:e1008994. PubMed
  27. Geisness AC, et al. 2021. Haematologica. Online ahead of print. PubMed
  28. Janune D, et al. 2011. FEBS Lett. 585:3033. PubMed
  29. Park HB, et al. 2020. Oncoimmunology. 9:1772663. PubMed
  30. Ries M, et al. 2017. PLoS Pathog. 10.1371/journal.ppat.1006506. PubMed
  31. Steinbuck MP, et al. 2021. Sci Adv. 7: . PubMed
  32. Acharya A, et al. 2020. J Virol. 95:e01657. PubMed
  33. Takushi SE, et al. 2020. Hum Gene Ther. 31:626. PubMed
  34. Shenoy AT, et al. 2021. Nat Commun. 12:5834. PubMed
  35. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  36. Elliott PR, et al. 2021. Cell Rep. 37:109777. PubMed
  37. Bunting MD, et al. 2022. Sci Adv. 8:eabk3327. PubMed
  38. Uddin MN, et al. 2022. Brain Behav Immun Health. 26:100563. PubMed
  39. Mittal P, et al. 2020. Cancers (Basel). :12. PubMed
  40. Gross C, et al. 2016. Neurol Neuroimmunol Neuroinflamm. 3: e289. PubMed
  41. Orlov M, et al. 2017. PLoS One.. 10.1371/journal.pone.018296. PubMed
  42. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  43. Vacaflores A, et al. 2016. PLoS One. 11: 0157175. PubMed
  44. Johnson AM, et al. 2020. J Immunol. 204:2295. PubMed
  45. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  46. Huang RS, et al. 2021. Curr Protoc. 1:e246. PubMed
  47. Nice T, et al. 2016. PLoS One. 12: 1005684. PubMed
  48. Krishnan A, et al. 2020. Am J Pathol. 190:1284. PubMed
  49. Ngwenyama N, et al. 2019. JCI Insight. 4:e125527. PubMed
  50. Chen YF, et al. 2019. J Biomed Sci. 26:85. PubMed
  51. Loeuillard E, et al. 2020. J Clin Invest. 130:5380. PubMed
  52. Liu X, et al. 2009. J Immunol. 183:51:00. PubMed
  53. Gladow N, et al. 2020. PLoS One. 15:e0227734. PubMed
  54. de Picciotto S, et al. 2022. Nat Commun. 13:3866. PubMed
  55. Shafer S, et al. 2021. J Allergy Clin Immunol. 148:256. PubMed
  56. Teh MR, et al. 2021. Front Immunol. 12:714613. PubMed
  57. Ren Y, et al. 2015. Biochim Biophys Acta. Available online 14 August 2015. PubMed
  58. Mandour MF, et al. 2020. Infect Agent Cancer. 15:30. PubMed
  59. Wood M, et al. 2011. Infect Immun. 79:708. PubMed
  60. Dimeloe S, et al. 2016. J Immunol. 196: 106 - 114. PubMed
  61. Bunse C, et al. 2013. PLoS One. 8:77925. PubMed
  62. Sabag B, et al. 2022. Cancers (Basel). 14:. PubMed
  63. FitzPatrick MEB, et al. 2021. Cell Rep. 34:108661. PubMed
  64. Landi A, et al. 2017. Vaccine.. 10.1016/j.vaccine.2017.10.072. PubMed
  65. Liu X, et al. 2020. Ther Adv Med Oncol. 12:1758835920910347. PubMed
  66. Burger ML, et al. 2021. Cell. 184:4996. PubMed
  67. Bonavita E, et al. 2020. Immunity. 1215:53. PubMed
  68. Mackroth M, et al. 2016. PLoS Pathog. 12:e1005909. PubMed
  69. Seenappa LM, et al. 2022. NPJ Vaccines. 7:128. PubMed
  70. Krishna B, et al. 2016. Sci Rep. 6: 24674. PubMed
  71. Schridde A, et al. 2017. Mucosal Immunol. 10.1038/mi.2016.142. PubMed
  72. Ruland C, et al. 2017. Brain Behav Immun. 10.1016/j.bbi.2017.06.010. PubMed
  73. Mattarollo S, et al. 2010. J Immunol. 184:5663. PubMed
  74. Spiljar M, et al. 2021. Cell Metab. 33:2231. PubMed
  75. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
  76. Marvin S, et al. 2017. J Virol. 10.1128/JVI.01417-16. PubMed
  77. Kumar S, et al. 2021. JCI Insight. 6:e145228. PubMed
  78. Fujiwara Y, et al. 2021. Nat Commun. 12:5857. PubMed

Antigen Details

Antigen References

1. Current Protocols in Immunology (John Wiley & Sons New York) Unit 6.24 Detection of Intracellular Cytokines by Flow Cytometry (Barbara Foster and Calman Prussin NIAID NIH Bethesda MD).
2. Sander B, et al. 1991. Immunol. Rev. 119:65.
3. Sander B, et al. 1993. J. Immunol. Meth. 166:201.
4. Prussin C, et al. 1995. J. Immunol. Meth. 188:117.
5. Jung T, et al. 1993. J. Immunol. Meth. 159:197.

Gene ID
NA

Related FAQs

How do I choose monensin or Brefeldin A solution?

Generally, Brefeldin A is more toxic for longer term incubations, so for shorter stimulations (6 hrs or less) use Brefeldin A.  For longer stimulations use monensin.  We recommend optimization for each cell type and protocol.

Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

ProductsHere

Login / Register
Remember me
Forgot your password? Reset password?
Create an Account